^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) + letrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
HER2-Negative and postmenopausal or premenopausal receiving ovarian ablation or suppression: Preferred Regimens...First-Line therapy, Selective ER down-regulator (fulvestrant, category 1) with/without nonsteroidal aromatase inhibitor (anastrazole, letrozole) (category 1).
Source:
Title:
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Excerpt:
......
Trial ID:
Source:
Title:
A Phase 1b/2 Study of PF-07220060 in Combination with PF-07104091 Plus Endocrine Therapy in Participants with BC and other Advanced Solid Tumors
Excerpt:
...• Male and female participants ≥18 years of age at Visit 1.• Histological or cytological diagnosis of locally advanced or metastatic solid tumor/diagnosis which is unresectable.• Evaluable lesion (including skin or bone lesion only, Part 1)• Participants entering the study in the expansion cohort have at least 1 measurable lesion as defined by RECIST (version 1.1) that has not been previously irradiated.• Cancer type: • HR-positive HER2-negative tumor (Part 1 and Part 2) • HR-positive HER2-positive tumor (Part 1) • Advanced solid tumor or metastatic disease (Part 1) • ECOG PS 0 or 1....
Trial ID:
